Read more on P-BCMA-ALLO1 “showing promise in multiple myeloma” as featured in GEN | View our supporting IMS data here

Latest data from Poseida’s lead investigational allogeneic CAR-T program, which is based on the Company’s unique stem cell memory T cell (T SCM ) platform Company to host conference call on Saturday, September 28, 2024 , at 1 PM ET / 10 AM PT to review the P-BCMA-ALLO1 Phase 1 IMS oral presentation